Inclusion Criteria

DISEASE CHARACTERISTICS: Diagnosis of non-Hodgkin's lymphoma (NHL) Relapsed disease OR
Refractory to first line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)
chemotherapy No myelodysplastic syndrome or chronic myeloid leukemia

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:
Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count
at least 150,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than 1.5 mg/dL OR
Creatinine clearance greater than 60 mL/min Other: Not pregnant or nursing Negative
pregnancy test Fertile patients must use effective barrier contraception No other prior
malignancy except: Curatively treated basal cell or squamous cell carcinoma Carcinoma in
situ of the cervix Surgically cured malignancy No hypersensitivity to E. coli derived
products (e.g., filgrastim (G-CSF), insulin, asparaginase)

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow or peripheral blood stem
cell (PBSC) transplantation for NHL No prior filgrastim-SD/01 No other concurrent
myelopoietic growth factors No concurrent WBC transfusions No concurrent PBSC collection
Chemotherapy: See Disease Characteristics No more than 2 prior courses of chemotherapy for
any malignancy Endocrine therapy: No concurrent corticosteroids except topical steroids or
as premedications or associated with chemotherapy Radiotherapy: At least 4 weeks since
prior radiotherapy Surgery: Not specified Other: At least 72 hours since prior
antimicrobials At least 30 days since other prior investigational drug No other concurrent
investigational drug No concurrent prophylactic antibiotics during course 1